paediatric

Special journal issue on pediatric genomic medicine

James Buchanan Other , , , , , , , , , , , , ,

Clinical Therapeutics (CT) is seeking papers for a specialty topic update on value, implementation, and access to pediatric genomic medicine. This themed section will be co-edited by Tara Lavelle and Hadley Stevens Smith. Additional information about topics of interest and the journal can be found here.

If you are interested in contributing, please send Tara and Hadley an email by July 31 that includes the title, article type (original article, review, or commentary), and abstract (< 400 words) of your proposed manuscript. They will be in touch after abstracts are evaluated to communicate the deadline for the full manuscript. All invited papers will undergo rigorous peer review and will not be subject to submission fees or page charges.

Please share this Call for Papers with colleagues and students who are working on issues of value, implementation, and access to pediatric genomic medicine, as Tara and Hadley hope to recruit a diverse array of experts for this special edition.

Contact details for Tara and Hadley are as follows:

  • Tara Lavelle, PhD (tlavelle@tuftsmedicalcenter.org) | Assistant Professor, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center
  • Hadley Stevens Smith, PhD, MPSA (hadley.smith@bcm.edu) | Postdoctoral Research Fellow in Health Policy, Center for Medical Ethics and Health Policy, Baylor College of Medicine | Incoming faculty, Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute

Whole genome sequencing costs – a step in the right direction

James Buchanan Paper review , , , , , , , , , , , , , , ,

It is now well documented that health economic evidence to inform commissioning decisions regarding genomic tests is in short supply. This lack of evidence relates to both costs and health outcomes – there is perhaps an understandable tendency to focus on the issues surrounding the measurement of health outcomes in genomics, but data on costs is equally sparse and the generation of such data is also beset by practical and methodological challenges. That said, in the past twelve months we have started to finally see some good quality data emerging on the costs of whole genome and whole exome sequencing, and a recent paper by Kate Tsiplova and colleagues has made a notable contribution to this literature.

Continue reading →